Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EBMT 2016 | The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia

Name: The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
Uploaded: 2016-04-04T00:00:00.000Z
Duration: 2 min 44 s

Chiara Bonini • 4 Apr 2016

EBMT 2016

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia

TK008

Chiara Bonini, MD, from San Raffaele Scientific Institute, Milan, Italy, gives an overview of the ongoing randomized Phase III trial TK008 (NCT00914628), which looks at the ability of donor lymphocytes to recognize and kill leukemia cells and the control of graft-versus-host-disease (GvHD) via the use of a suicide gene in high-risk leukemia patients who underwent haploidentical hematopoietic cell transplantation. The aim is immunoreconstitution, a reduced relapse rate and control of GvHD. According to Prof Bonini, the killing of the gene modified cells and the control of GvHD has been reported as efficient in several studies.